Pre-existing diabetes and lung cancer prognosis.
Pre-existing diabetes and lung cancer prognosis.
复制标题
DOI：
10.1038/bjc.2016.141
复制
发表时间：
2016-06-28
影响因子：
8.8
通讯作者：
Margolis KL
中科院分区：
文献类型：
--
作者：
Luo J;Hendryx M;Qi L;Ho GY;Margolis KL
本研究的目的是调查既存糖尿病和糖尿病治疗对肺癌预后的影响。共有2484名妇女从妇女健康倡议中确诊肺癌事件，平均随访2.9年，直至死亡日期或2014年8月29日。与患有肺癌但未患糖尿病的女性相比，患有肺癌和糖尿病的女性的总体死亡风险显著增加（HR=1.27，95%CI：1.07-1.50）。接受胰岛素或二甲双胍治疗的糖尿病女性或糖尿病持续时间较长的女性总体死亡风险也增加。我们的大型前瞻性研究提供的证据表明，既存糖尿病与肺癌女性患者的总体生存率相关，但不支持二甲双胍使用可能对肺癌和糖尿病女性患者具有保护作用的假设。
The aims of this study are to investigate the impact of pre-existing diabetes and diabetes treatments on lung cancer prognosis. A total of 2484 women with confirmed incident lung cancer from the Women's Health Initiative were followed for an average of 2.9 years through the date of death or 29 August 2014. Compared with women with lung cancer but without diabetes, women with lung cancer and diabetes had significantly increased risk of overall mortality (HR=1.27, 95% CI: 1.07–1.50). Women with diabetes receiving insulin or metformin or women who had long duration of diabetes also had increased risk of overall mortality. Our large prospective study provides evidence that pre-existing diabetes is associated with poor overall survival among women with lung cancer, but do not support the hypothesis that metformin use may have a protective effect in women with lung cancer and diabetes.